All Stories

  1. Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

    Article • Cancer Management and Research, February 2019, Dove Medical Press

    Dr Munira Borhany, Bushra Kaleem, SIDRA MAQSOOD